Lilly Pennsylvania plant breaks ground with capacity built for unapproved retatrutide
Eli Lilly started building a 3.5 billion dollar injectables and device site in Fogelsville, due to run by 2031. Its first named product, the triple hormone peptide retatrutide, is still in Phase 3 trials.
FOGELSVILLE, PA
- What's newEli Lilly broke ground on a 3.5 billion dollar injectable medicine and device site in Fogelsville, Pennsylvania, first announced in February 2026, with about 850 permanent jobs planned.
- Why it mattersThe plant is built to make next generation obesity drugs, led by retatrutide, a triple hormone peptide that is still in Phase 3 trials and not approved anywhere.
- What's nextLilly expects the site to be running by 2031. No retatrutide filing date has been announced, so approval and demand remain open questions.